RAD 2025: Long-Term Data on Nemluvio ® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to

[
RAD 2025: Long-Term Data on Nemluvio ® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to
[og_img]
https://www.investing.com/news/press-releases/rad-2025-longterm-data-on-nemluvio–nemolizumab-demonstrate-its-favorable-safety-profile-and-sustained-and-increased-improvements-in-itch-and-skin-lesions-in-patients-with-atopic-dermatitis-up-to-93CH-4084333


Investing.com